Literature DB >> 15732028

Anemia and new-onset congestive heart failure in the general Medicare population.

Peter E Sandgren1, Anne M Murray, Charles A Herzog, Craig A Solid, David T Gilbertson, Allan J Collins, Robert N Foley.   

Abstract

BACKGROUND: Anemia is associated with disease severity and prognosis for patients with congestive heart failure (CHF). It is unknown whether anemia is associated with the development of new-onset CHF in the elderly. METHODS AND
RESULTS: This retrospective longitudinal cohort study used the Medicare 5% database. In the incident analysis, the study sample comprised subjects without CHF in 1999 (n = 1,063,495); the main exposure variable evaluated was the presence or absence of anemia in 1999; and the primary study outcome was the occurrence of new-onset CHF. The prevalence of chronic anemia and CHF in 1999 was 5.0% and 9.9%, respectively. The incidence of new-onset CHF in 2000 in those with and those without anemia in 1999 was 12.3% and 5.9%, respectively, corresponding to an adjusted hazard ratio of 1.29 ( P < .001), a value intermediate between the hazard ratios of 1.13 ( P < .001), and 1.76 ( P < .001) associated with hypertension and atherosclerotic heart disease, respectively. Anemia also was associated with death in the year after new-onset CHF (adjusted hazard ratio, 1.28; P < .001).
CONCLUSION: Anemia in the Medicare population is associated with the diagnosis and prognosis of new-onset CHF.

Entities:  

Mesh:

Year:  2005        PMID: 15732028     DOI: 10.1016/j.cardfail.2004.06.435

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  9 in total

1.  Impact of Chronic Anemia on the New-Onset Atrial Fibrillation in the Elderly: It May Not Be What We Have Thought.

Authors:  Harsha V Ganga; Nandini Kolla; M Bridget Zimmerman; Wayne L Miller
Journal:  J Atr Fibrillation       Date:  2012-04-14

Review 2.  Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists.

Authors:  Donald S Silverberg; Dov Wexler; Adrian Iaina; Shoshana Steinbruch; Y Wollman; Doron Schwartz
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 3.  Anaemia in diabetes: Is there a rationale to TREAT?

Authors:  M C Thomas; M E Cooper; K Rossing; H H Parving
Journal:  Diabetologia       Date:  2006-04-04       Impact factor: 10.122

Review 4.  Cardiorenal syndrome: pathophysiology and potential targets for clinical management.

Authors:  Parta Hatamizadeh; Gregg C Fonarow; Matthew J Budoff; Sirous Darabian; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2012-12-18       Impact factor: 28.314

5.  Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer.

Authors:  Louise Emilsson; Xabier García-Albéniz; Roger W Logan; Ellen C Caniglia; Mette Kalager; Miguel A Hernán
Journal:  JAMA Oncol       Date:  2018-01-01       Impact factor: 31.777

6.  Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study.

Authors:  S Heleen Binnenmars; Georgette E Hoogslag; Stanley M H Yeung; Frank P Brouwers; Stephan J L Bakker; Wiek H van Gilst; Ron T Gansevoort; Gerjan Navis; Adriaan A Voors; Martin H de Borst
Journal:  J Am Heart Assoc       Date:  2022-07-25       Impact factor: 6.106

Review 7.  Management of cardiorenal metabolic syndrome in diabetes mellitus: a phytotherapeutic perspective.

Authors:  Min Kyong Song; Neal M Davies; Basil D Roufogalis; Tom Hsun-Wei Huang
Journal:  J Diabetes Res       Date:  2014-04-13       Impact factor: 4.011

Review 8.  Type 2 Diabetes and Heart Failure: Challenges and Solutions.

Authors:  Merlin C Thomas
Journal:  Curr Cardiol Rev       Date:  2016

9.  Perspective Review: Type 2 Diabetes and Readmission for Heart Failure.

Authors:  Merlin C Thomas
Journal:  Clin Med Insights Cardiol       Date:  2018-06-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.